Literature DB >> 6234201

High-level expression of human interferon gamma in Escherichia coli under control of the pL promoter of bacteriophage lambda.

G Simons, E Remaut, B Allet, R Devos, W Fiers.   

Abstract

Several recombinant plasmids have been constructed which direct high-level synthesis of mature human interferon gamma (IFN-gamma) in Escherichia coli using the inducible leftward promoter pL of phage lambda followed by a translational initiator region derived either from the phage MS2 replicase gene or the E. coli tryptophan attenuator region. Under these conditions, IFN levels of up to 25% of the total cellular protein can be achieved. The highest levels were obtained when a terminator of transcription was cloned downstream from the IFN-gamma sequence. IFN-gamma was almost entirely found in the initial pellet fraction and not in soluble extracts. Co-induction of the lysis genes derived from phage MS2 or from phage lambda, inserted downstream from the IFN-gamma sequence, did not enhance the biological activity present in the supernatant fraction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6234201     DOI: 10.1016/0378-1119(84)90087-8

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  21 in total

1.  Production of recombinant human glucagon in the form of a fusion protein in Escherichia coli; recovery of glucagon by sequence-specific digestion.

Authors:  J Ishizaki; M Tamaki; M Shin; H Tsuzuki; K Yoshikawa; H Teraoka; N Yoshida
Journal:  Appl Microbiol Biotechnol       Date:  1992-01       Impact factor: 4.813

2.  Production and characterization of human gamma interferon from Escherichia coli.

Authors:  L Perez; J Vega; C Chuay; A Menendez; R Ubieta; M Montero; G Padron; A Silva; C Santizo; V Besada
Journal:  Appl Microbiol Biotechnol       Date:  1990-07       Impact factor: 4.813

3.  Use of controlled luciferase expression to monitor chemicals affecting protein synthesis.

Authors:  J Lampinen; M Virta; M Karp
Journal:  Appl Environ Microbiol       Date:  1995-08       Impact factor: 4.792

4.  Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma.

Authors:  E M Lemmel; M Franke; W Gaus; P W Hartl; P H Hofschneider; K Miehlke; K Machalke; H J Obert
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

5.  Use of Bacillus brevis for efficient synthesis and secretion of human epidermal growth factor.

Authors:  H Yamagata; K Nakahama; Y Suzuki; A Kakinuma; N Tsukagoshi; S Udaka
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

6.  The use of two-cistron constructions in improving the expression of a heterologous gene in E. coli.

Authors:  A J Makoff; A E Smallwood
Journal:  Nucleic Acids Res       Date:  1990-04-11       Impact factor: 16.971

7.  Stimulation of hematopoiesis in vivo by recombinant bacterial murine interleukin 3.

Authors:  V Kindler; B Thorens; S de Kossodo; B Allet; J F Eliason; D Thatcher; N Farber; P Vassalli
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

8.  Cloning and expression of T4 DNA polymerase.

Authors:  T C Lin; J Rush; E K Spicer; W H Konigsberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

9.  A broad-host-range expression vector based on the pL promoter of coliphage lambda: regulated synthesis of human interleukin 2 in Erwinia and Serratia species.

Authors:  R Leemans; E Remaut; W Fiers
Journal:  J Bacteriol       Date:  1987-05       Impact factor: 3.490

10.  Recombinant human glucagon: large-scale purification and biochemical characterization.

Authors:  K Yoshikawa; H Tsuzuki; M Fujimoto; M Tohkin; T Matsubara; H Yonezawa; H Okamoto; H Teraoka; N Yoshida
Journal:  J Protein Chem       Date:  1992-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.